COST-EFFECTIVENESS ANALYSIS OF EXENATIDE ONCE-WEEKLY VERSUS DULAGLUTIDE, LIRAGLUTIDE AND LIXISENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM THE UK NHS PERSPECTIVE

被引：1
|
作者：
Charokopou, M. [1 ]
Chuang, L. [1 ]
Verheggen, B. [1 ]
Gibson, D. [2 ]
Grandy, S. [3 ]
Kartman, B. [4 ]
机构：
[1] Pharmerit Int, Rotterdam, Netherlands
[2] AstraZeneca, Luton, Beds, England
[3] Astrazeneca Pharmaceut LP, Gaithersburg, MD USA
[4] AstraZeneca, Molndal, Sweden
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2090
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB50
引用
收藏
页码：A606 / A606
页数：1
相关论文
共 50 条
  • [31] Once-weekly exenatide as a treatment for Type 2 diabetes
    Schauerhamer, Marisa B.
    Gurgle, Holly
    McAdam-Marx, Carrie
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (06) : 611 - 626
  • [32] Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus
    Ryan, Gina J.
    Moniri, Nader H.
    Smiley, Dawn D.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (13) : 1123 - 1131
  • [33] Once-weekly semaglutide provides better health outcomes compared to dulaglutide as dual therapy in the treatment of type 2 diabetes: a cost-effectiveness analysis
    Tikkanen, C. K.
    Johansen, P.
    Hunt, B.
    Malkin, S.
    Pollock, R. F.
    DIABETOLOGIA, 2018, 61 : S426 - S427
  • [34] Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial
    Becker, Frauke
    Dakin, Helen A.
    Reed, Shelby D.
    Li, Yanhong
    Leal, Jose
    Gustavson, Stephanie M.
    Wittbrodt, Eric
    Hernandez, Adrian F.
    Gray, Alastair M.
    Holman, Rury R.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 183
  • [35] Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
    Becker, F.
    Dakin, H.
    Reed, S. D.
    Li, Y.
    Leal, J.
    Gustavson, S. M.
    Kartman, B.
    Wittbrodt, E.
    Gray, A. M.
    Hernandez, A. F.
    Holman, R. R.
    DIABETOLOGIA, 2018, 61 : S366 - S366
  • [36] Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
    Zhen Ruan
    Carolina Oi Lam Ung
    Yang Shen
    Yawen Zhang
    Weihao Wang
    Jingyi Luo
    Huimin Zou
    Yan Xue
    Yao Wang
    Hao Hu
    Lixin Guo
    Diabetes Therapy, 2022, 13 : 1737 - 1753
  • [37] Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
    Ruan, Zhen
    Ung, Carolina Oi Lam
    Shen, Yang
    Zhang, Yawen
    Wang, Weihao
    Luo, Jingyi
    Zou, Huimin
    Xue, Yan
    Wang, Yao
    Hu, Hao
    Guo, Lixin
    DIABETES THERAPY, 2022, 13 (10) : 1737 - 1753
  • [38] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Gabriela Vega-Hernandez
    Radek Wojcik
    Max Schlueter
    Diabetes Therapy, 2017, 8 : 513 - 530
  • [39] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Vega-Hernandez, Gabriela
    Wojcik, Radek
    Schlueter, Max
    DIABETES THERAPY, 2017, 8 (03) : 513 - 530
  • [40] COST-EFFECTIVENESS OF ONCE WEEKLY DULAGLUTIDE 1.5 MG VERSUS ONCE DAILY LIRAGLUTIDE 1.8 MG FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CHINA
    Han, S.
    Guo, W. J.
    Wang, K.
    McKaig, S.
    Strizek, A. A.
    Shi, L. W.
    VALUE IN HEALTH, 2019, 22 : S167 - S167
12345